Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00194896 · ClinicalTrials.gov registry record · NA
Preferred Treatment of Type 1.5 Diabetes
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT00194896 is a NA study that has completed, run by University of Washington. The registered enrollment target is 64 participants.
The verdict
NCT00194896, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide.
Interventions
- DRUG rosiglitazone
- DRUG glyburide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2000-02 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00194896
The ClinicalTrials.gov registry entry for NCT00194896 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rosiglitazone is the first listed.
NCT00194896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00194896 about?
NCT00194896 is a clinical study titled "Preferred Treatment of Type 1.5 Diabetes". The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of b...
What is the current status of trial NCT00194896?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2000-02. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00194896?
The interventions under investigation include: rosiglitazone (DRUG), glyburide (DRUG).
Who is sponsoring clinical trial NCT00194896?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.